I'm definitely in that camp, FDA approval was priced in long ago. That boat left the dock when we received very positive feedback from the FDA last year. What's not priced in are the sales and earnings to come (in my view). I don't think the market is thinking about just how large the addressable market is, nor is it considering all the future products/indications that will further expand that addressable market. That's why I continue to be very bullish on this.
Ann: FDA Approves Sofdra, page-492
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.5¢ | $1.302M | 3.974M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 713153 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 215665 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |